NCT05041101: Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Inflammatory breast cancer (IBC)
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Chemotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with HER2+ breast cancer must have had progression on Herceptin/trastuzumab, Perjeta/pertuzumab, & Kadcyla/T-DM1
Exclusions: Patients with exposure to eribulin; Patients with symptomatic, untreated, unstable brain leptomeningeal metastases

Comments are closed.

Up ↑